Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
September 28, 2020
Earnings Call Speaker Segments
Operator
operatorHello everyone, and thanks for joining us for the Palatin Technologies call covering results for the fourth quarter and the close of fiscal year 2020. Please note that this call is being recorded. Before I get into our prepared remarks, I want to point out that any statements from Palatin that aren't historical facts could constitute forward-looking statements. Such statements rest on assumptions that might or might not turn out to be correct, and actual outcomes could differ substantially from what we expect because of various risks and uncertainties described in the Company's latest filings with the Securities and Exchange Commission. We encourage you to weigh those risks and uncertainties carefully as you evaluate these forward-looking statements and Palatin's prospects. At this point, I'll hand things over to Dr. Carl Spana, our President and Chief Executive Officer, who is hosting today's call. Go ahead, sir.
Carl Spana
executiveThanks. Good morning, and welcome to the call for Palatin Technologies' fourth quarter and fiscal year-end 2020. I'm Dr. Carl Spana, CEO and President of Palatin's. Joining me today is Steve Wills, Palatin's Executive Vice President, Chief Financial Officer and Chief Operating Officer. During this call, we'll give financial and operating updates, including how the COVID-19 pandemic has affected us. We truly hope that you and your families are safe and healthy as you cope with the life-altering changes the COVID-19 pandemic has brought about. Today Steve will give a financial update, along with an update on our reacquisition of Vyleesi from AMAG Pharmaceuticals. My update will center on the progress of our development programs, specifically PL-9643 for dry eye disease, Phase 2, and the PL-8177 COVID-19 program. Steve?
Steve Wills
executiveThanks, Carl, and good morning, everyone. I'll begin with the financial update, covering the highlights for the fourth quarter and fiscal year 2020. For the quarter that closed on June 30, 2020, we recorded a net loss of $7.3 million, or $0.03 per basic and diluted share, versus net income of $52.2 million, or $0.25 per basic share and $0.23 per diluted share, in the same quarter of 2019. For the year ended June 30, 2020, the net loss came to $22.4 million, or $0.10 per basic and diluted share, compared with net income of $35.8 million, or $0.17 per basic share and $0.16 per diluted share, for the year ended June 30, 2019. The swing between net loss and net income for both the quarter and the year ended June 30, 2020, relative to the quarter and year ended June 30, 2019, stemmed from recognizing license and contracts revenue under our license agreement with AMAG totaling $60.3 million in the quarter and year ended June 30, 2019. At June 30, 2020, Palatin held $82.9 million in cash and cash equivalents, up from $43.5 million at June 30, 2019, and carried no debt. We believe our existing capital resources will be enough to fund planned operations through at least September 30, 2021.
Steve Wills
executiveWith roughly $83 million in cash as of June 30, 2020, and carrying no debt, together with the $12 million that came in from AMAG in July 2020, plus another $4.3 million owed by AMAG on March 31, '21, we have the financial wherewithal to push our Anti-Inflammatory and Autoimmune programs forward in a meaningful way and to make complementary, targeted investments in our Vyleesi program. Turning to Vyleesi, it holds FDA approval for premenopausal women who have hypoactive sexual desire disorder, or HSDD. For premenopausal women experiencing distress or interpersonal difficulty stemming from low sexual desire, Vyleesi stands as the first and only FDA-approved product for as-needed treatment. It comes as a subcutaneous self-injection in a prefilled, disposable autoinjector pen, used in anticipation of a sexual encounter. HSDD is estimated to affect one in ten premenopausal women. To recap the history, Palatin licensed North American rights for Vyleesi to AMAG during the first quarter of 2017, and we got $60 million as an upfront payment. Between the second quarter of 2017 and the first quarter of 2018, Palatin collected $25 million in cost reimbursement along with a $20 million regulatory milestone tied to the FDA's acceptance of the NDA.
Steve Wills
executiveThe FDA approved Vyleesi back in June 2019. At that point, Palatin got a regulatory milestone worth $60 million. All told, we have brought in roughly $165 million since the first quarter of 2017. In January 2020, AMAG said that following a strategic review of its assets and business model, it had chosen to start a process aimed at divesting Vyleesi along with another women's healthcare product. Then in July 2020, Palatin announced that its license agreement with AMAG for Vyleesi had been ended by mutual agreement. Per the terms of that termination agreement, Palatin got back all North American rights to develop and commercialize Vyleesi. AMAG paid Palatin $12 million at closing, and it will pay Palatin $4.3 million on March 31, 2021. Palatin took on every Vyleesi manufacturing agreement, and AMAG will hand over all information, data, and assets tied exclusively to Vyleesi, including but not limited to existing inventory carried at a cost of about $15 million. For a period of time, AMAG will furnish certain transitional services to Palatin so that patients keep having access to Vyleesi and regulatory compliance is maintained while the transition back to Palatin takes place. Palatin will reimburse AMAG for the transition services costs that were agreed upon. We see Vyleesi as an important treatment for the millions of premenopausal women who suffer from HSDD.
Steve Wills
executiveWith the Vyleesi program, what we aim to do is show value in the marketplace by boosting demand from patients and their access. Our objective is to relicense the U.S. rights to a committed women's healthcare company. We've taken steps so that patient access to Vyleesi is not disrupted, and we're working to broaden awareness of the condition and the treatment in a highly targeted and informed manner, to enhance and streamline patient access, and to increase insurance coverage. Palatin is exploring its options for enhancing the commercialization of Vyleesi, including but not limited to discussions with potential collaboration partners that currently market female healthcare products. Palatin continues collaboration discussions for territories outside the currently licensed territories of China and Korea, and anticipates executing multiple agreements through calendar 2021. In the interim, Palatin's strategy implements an informed and highly targeted approach to marketing, focusing on telemedicine, social media, and digital advertising. We are committed to working with payers and healthcare professionals to ensure women with HSDD have continued and affordable access to Vyleesi. Vyleesi remains commercially available through specialty pharmacies Avella and BioPlus, and patients also have the ability to connect with a healthcare provider through telemedicine. I'll now turn the call back over to Carl.
Carl Spana
executiveThanks, Steve. Over the last 12 months, we took Vyleesi back in-house and <<inaudible>> dealt with the worldwide COVID-19 pandemic — 2 big hurdles nobody saw coming, and both have altered how our company runs. Because our company is well financed and well managed, we've been able to tackle these hurdles effectively, with only minimal disruption to operations. I'll begin the operational update with how COVID-19 has affected us. Our top priorities have been keeping our employees, patients and healthcare partners safe. Early in March we put a work from home policy in place, and it stays in force for our office staff. During the past quarter, we reopened our research laboratory. Luckily, the majority of our key research and development partners are still operating. Through teleconferences on a range of online meeting platforms, we've been effective at keeping our programs moving forward. That said, we recognize that even with activities resuming, business activity could face additional disruptions if the virus resurges, and we'll be ready for that possibility. In July 2020, we required Vyleesi from AMAG Pharmaceuticals. As a reminder, AMAG's divestiture of Vyleesi stemmed from strategic and operational changes at AMAG, not from what Vyleesi might be worth.
Carl Spana
executiveWe've gone over the specifics of the reacquisition along with the strategy and operational goals for Vyleesi. With this direction in place, we've put together a strong and highly motivated commercial team committed to showing what Vyleesi is worth. Our belief is that this strategy will let us demonstrate Vyleesi's potential value in a cost-effective way. The end goal is to relicense Vyleesi through a dedicated partner, which would secure continued availability as a treatment option for premenopausal women with HSDD as well as a financial return on our investment. Palatin's main scientific focus is the melanocortin system, which plays a part in regulating energy balance, including food intake, sexual function, and resolution of inflammatory responses. The first program we succeeded with in the melanocortin system was built on how that system regulates sexual function. That research effort led to the discovery of Vyleesi and, ultimately, to FDA approval as the first as-needed treatment for premenopausal women with HSDD. Our research today centers on developing drugs that target the melanocortin system's capacity to resolve or dial down inflammation. We have developed several drug candidates that, in preclinical models, have shown potential for resolving a range of inflammatory disease conditions.
Carl Spana
executiveStudies that we and other groups have carried out indicate that when melanocortin drugs are aimed at immune cells, pro-inflammatory processes get resolved. Among these pro-resolution effects are shifting immune cells from an inflammatory state into a regulatory one, blocking production of pro-inflammatory cytokines including TNF-alpha, interleukin-6 and others, and raising levels of anti-inflammatory cytokines such as interleukin-10. Beyond that, the melanocortin system helps lessen the fibrotic response that arises as a component of numerous inflammatory diseases. Fibrosis caused by inflammatory disease leaves patients facing negative health consequences over the long term. For that reason, we think melanocortin drugs that target the immune system will be broadly useful for treating inflammatory diseases. We have created drug candidates at clinical stage for ocular conditions including dry eye disease, non-infectious uveitis and retinal diseases. We additionally have a clinical stage drug cabinet for gastrointestinal diseases including ulcerative colitis. Our melanocortin drugs aimed at the immune system, PL-9643, and a Phase 2 study in dry eye disease employing an eye drop formulation in January, 2020. Dry eye disease, also called keratoconjunctivitis sicca, impacts the cornea and the conjunctiva of the eye, producing irritation, redness, pain and blurred vision.
Carl Spana
executiveThe reasons behind it differ from case to case, and our belief is that PL-9643, by activating the melanocortin system in a localized way, will bring down the inflammation responsible for many of the negative features of dry eye disease. By July of 2020, enrollment was complete, with 160 dry eye disease patients in the study, and we remain on schedule to report data in the fourth quarter of calendar 2020. If the study succeeds, it will generate the data needed to move PL-9643 ophthalmic solution into pivotal Phase 3 studies, which are set to begin in the first half of 2021. Since data are coming later this year, I want to walk through the trial design, our regulatory strategy, and what a successful trial might look like. Endpoints in dry eye disease clinical studies fall into two categories: signs and symptoms. A sign is direct evidence of disease. Corneal lesions and tear production are examples. Symptoms are aspects of disease that patients experience, and examples include blurry vision and itchy eyes. Phase 3 pivotal studies will need to reach statistical significance on the co-primary endpoints of a sign and a symptom of dry eye disease. The PL-9643 Phase 2 dry eye disease study is a multicenter randomized control study comparing PL-9643 to placebo over a 12-week treatment period. The co-primary endpoints are a sign of dry eye disease, which in this case is inferior corneal fluorescein staining, and a secondary symptom, which is ocular discomfort.
Carl Spana
executiveWe’ve also built in a number of secondary endpoints that assess how PL-9643 affects the signs and symptoms of dry eye disease. In a Phase 2 study with multiple secondary endpoints, it’s standard to rely on just one primary endpoint. Following our discussions with the FDA, we decided to use co-primary endpoints, and the approach for this current Phase 2 study could potentially serve as one of the two required Phase 3 pivotal studies if both co-primary endpoints reach statistical significance. The study has been designed so that multiple outcomes can support a successful move into a Phase 3 pivotal study. Those potential outcomes include statistical significance on both co-primary endpoints, statistical significance for inferior corneal fluorescein staining, and, among the secondary symptom endpoints, statistical significance for ocular discomfort, a secondary signed endpoint. This approach lowers Phase 2 risk and creates the possibility that the current Phase 2 study can count as one of the two required Phase 3 pivotal studies, cutting cost and time to a new drug application. The dry eye disease treatment market is a substantial commercial opportunity, with over $2 billion in annual sales and continued growth driven by patient demographics. We believe PL-9643’s potential efficacy and its stable tolerability and safety profile will enable substantial market penetration in the dry eye market.
Carl Spana
executiveTurning now to PL-8177, which is part of our program for pulmonary disease in COVID-19. PL-8177 has shown anti-inflammatory activity in preclinical disease models, along with the capacity to shield lung tissue from fibrosis-related damage. As a possible therapy for individuals infected with COVID-19, PL-8177 might lessen the inflammation and lung fibrosis tied to progressive disease. During the second quarter of calendar 2020, we had a conversation with BARDA regarding PL-8177 as a possible treatment for patients with COVID-19 infections. Among the outcomes from that conversation was guidance that we advance PL-8177 and open talks with the FDA about a possible PL-8177 clinical study in COVID-19 patients. In the second quarter of calendar 2020, we filed a pre-investigational new drug application data package with the FDA and obtained detailed guidance on what would be required to move PL-8177 into clinical studies. Consistent with our existing PL-8177 COVID-19 plan, we are carrying out every required activity necessary to file an IND and launch clinical studies of PL-8177 in COVID-19 patients. These encompass activities such as clinical protocol development, production by the contract research organization, identification of clinical trial sites, and manufacture of PL-8177 and placebo doses. We aim to finish these activities in the third quarter of calendar 2020.
Carl Spana
executiveBut scheduling tied to COVID-19 at the contract manufacturer we use means clinical study doses won't be available until the fourth quarter of calendar 2020. As a result, those activities are now set to wrap up in Q4 of this calendar year, which lets us submit an IND to the FDA and get clinical study of PL-8177 underway. As we've noted on earlier calls, in press releases and in our 10-K, the environment for treating patients and running clinical studies in COVID-19 is changing fast, and that affects the design, the risk and our ability to conduct clinical studies in COVID-19 patients. Having weighed the risk and uncertainty of running COVID-19 clinical studies, the launch of the PL-8177 clinical study depends on securing external funding and operational support, and we are currently applying to several government programs that offer that kind of support. Our clinical trial for retinal disease indications is now planned to start in the second half of calendar 2021. That works out to roughly a two quarter delay, caused by the impact of the COVID-19 pandemic. We are putting this extra time toward broadening our clinical and scientific knowledge of the melanocortin system and ocular inflammatory disease. With our oral disease formulations for PL-8177 and a treatment for ulcerative colitis updated to other inflammatory bowel diseases, we have completed all the necessary preclinical activities and drug product manufacturing to launch a Phase 2 proof of mechanism study, which is targeted to begin patient enrollment in the first half of calendar 2021.
Carl Spana
executiveSo to wrap up, drawing on the research we've done on the natriuretic peptide system, our drug candidate PL-3994 — together with naturally occurring peptide receptor A agonists — is going to be assessed in a Phase 2A clinical study involving heart failure patients who have preserved ejection fraction. This clinical study is being run in collaboration with two major academic medical centers, and an American Heart Association Grant is providing support for it. Every approval we need is now in place, and the drug needs to be supplied to the clinical trial site. We anticipate the study's first patient will come in the fourth quarter of calendar 2020. More details about our programs are available on our website, www. peletin.com. The past year has certainly brought its challenges, with multiple external events affecting how we operate. In response, our executive management, employees and board of directors had to adjust our business operations quickly, and we have been able to keep advancing our programs. In addressing the COVID-19 pandemic, we took immediate actions to ensure the safety of our employees, patients and healthcare partners. We implemented operational processes that have allowed our employees to remain highly productive. Our ability to keep advancing our development programs, together with our healthy cash position, will allow Palatin to emerge from this pandemic in a strong position.
Carl Spana
executiveAt the same time, we'll stay diligent about having plans ready in case the virus comes back. A key event was getting back the North American rights to Vyleesi from AMAG Pharmaceuticals. We see real potential in Vyleesi as a treatment for premenopausal women with HSDD, and we view this as a chance to boost our company's value. With Steve Wills leading the effort, we've built a strong commercial team, and they intend to show Vyleesi's commercial value in support of our goal of licensing Vyleesi to a partner dedicated to realizing its worth. Our partners in China and Korea, with our backing, are now moving Vyleesi forward in clinical studies to support their regulatory filings for eventual approval and sale of Vyleesi in those markets. For our dry eye disease program, we started and finished enrollment in a Phase 2 clinical study, and we remain on track to have data by year-end calendar 2020. Should the study prove positive, we are positioned to advance into Phase 3 pivotal studies during the first half of calendar 2021. Looking ahead to 2021, we'll keep managing the operational challenges that the COVID-19 pandemic creates. We have a robust pipeline of novel clinical drug candidates, and we will stay focused on moving them forward.
Carl Spana
executiveDrawing on the research we finished over the past 12 months, we're now set to launch clinical trials in COVID-19 patients, ulcerative colitis, and retinal disease during 2021. To wrap up, I want to express my appreciation to the Palatin team and every one of our development partners for how quickly they adapted to a new working environment and for their ongoing commitment to moving Vyleesi forward, to our commercial activities, and to our novel drug candidates. Thank you — and at this point we'll open the call for questions.
Operator
operatorMuch appreciated. At this point, folks, we'd like to begin the Q&A session. <<operator_script>> Our initial question is from John Newman at Canaccord.
John Newman
analystI was just hoping you could expand a bit on the transitional service agreements in place for Vyleesi, and on how those are going to let you keep supporting commercialization of the product in the interim here. And also just how that's happening really at very low cost to you?
Steve Wills
executiveHi, John — this is Steve. Let me be direct: at Palatin, once we reached the point where we understood we'd be reclaiming the product and parting ways with AMAG, despite the payments and the releases, we recognized we needed to have any commercial and regulatory capabilities we lacked up and running, so we entered into a transitional services agreement with AMAG, and that's what we did. One area where we've consistently been very capable — as you remember, we created the product, and we spoke with CMC immediately — but matters concerning pharmacovigilance, quality, government reporting, and market access oversight, those were among the particular functions for which we brought in AMAG. So across the coming several months, we're working through moving every one of those functional areas over to Palatin, and that will involve either in-house staff or outside third-party resources. So we feel confident we have enough time to accomplish this in a well-organized, well-informed manner. And the key priority was ensuring every functional area stood ready under agreements, so that no disruption to patient access occurred, and also to make certain all regulatory compliance elements were handled.
John Newman
analystAll right, thank you. Next, I was curious about the dry eye data expected in Q4. I understand you'll be evaluating fluorescein staining. What I'd like to know is what we ought to pay attention to there — is it mostly just a readout on the primary endpoint, or should we also be looking at the signs and symptoms and similar measures?
Carl Spana
executiveAs I said on the call, John, the two requirements are signs and symptoms. Fluorescein staining measures inflammatory lesions in the eye. Inferior simply refers to the lower portion of the eye, and part of that is just because of how the study was conducted. Many times, the bottom of the eye can be somewhat drier. So my way of thinking about it is that this was a first attempt. By using co-primary endpoints, we took on a bit of risk. But I believe that risk is worthwhile, since if we do achieve both, we think this will qualify as one of the Phase 3 pivotal studies. But there is a whole host of — from an FDA standpoint, they are fairly agnostic; there are various signs one can use, and it's as simple as that one can use. The requirement, or for ultimate approval, is that you achieve one sign and one symptom in two Phase 3 registration studies. So on our end, as you said, there are multiple outcomes. Provided we achieve one of the two co-primaries and demonstrate very strong evidence of effect from something on the opposite side, we will move ahead, and we will move ahead and advance into Phase 3.
Carl Spana
executiveThat’s how I look at it. As for other areas I’d emphasize, ocular comfort matters a lot. The treatments available now — Restasis, Xiidra, and topical steroids — tend to come with tolerability problems, things like stinging, off case dumpiness <<inaudible>> and that sort of issue. So I’d say tolerability in the eye <<inaudible>> is a major commercial attribute — and comfort is a major commercial attribute that we believe PL 81 <<inaudible>> — PL 9 to 43 <<inaudible>> will offer.
Operator
operatorThanks a lot. Joseph Pantginis from H.C. Wainwright & Co. will be asking our next question.
Joe Pantginis
analystCarl, I want to pick up on something you said near the end of your prepared remarks, where you mentioned Steve and the commercial work happening right now for Vyleesi. So I was hoping you could share any specific details about (a) how you're actually keeping the profile high. I know you covered some of this in your prepared comments, but to be more specific, can you give us any sense of how scripts are trending and what kind of coverage Vyleesi has at present? Thanks.
Carl Spana
executiveI'll hand things over to Steve in just a moment. But first, I want to make one point that wasn't included in the prepared remarks. The distribution setup for Vyleesi had been established by AMAG via two specialty pharmacies, which Steve has described to you. Sadly, because AMAG pulled its backing for the product rather quickly in Q4 of last year, that distribution chain — getting the drug from the manufacturer to the pharmacy and then from the pharmacy to the patient — required some work, some tender loving care, as we put it, before we could truly begin assessing the marketing, or the targeted marketing, of Vyleesi, and we're now reaching that point. So even though from our side it has seemed very quiet, and I know investors keep reaching out asking what's happening, it has actually been an extremely busy stretch, especially for Steve and the commercial team, who have been ensuring that patient access — in other words, that the product flows through the system and that the patient experience is truly optimized. And he has done a great job on that front.
Carl Spana
executiveThese pharmacies are now truly operating at a significantly higher standard—really the standard they should be hitting—and we're finally able to start focusing on the marketing side of the program. With that said, I'll hand things over to Steve, and perhaps he can explain where he wants this program to go and where we plan to take it.
Steve Wills
executiveAs Carl said — and I think it might be useful here — if I take us back to the national launch, AMAG brought Vyleesi out in September. Within a few months, they had reached an average of 2,500 scripts each month, and that number was above their base projections. So frankly, things were going well. But then in January 2020, as we noted, after the strategic review of AMAG's business model, they chose to divest two of their assets — specifically, Vyleesi and Intrarosa. And despite that divestiture process, the investment and the marketing were switched off. They began going through reductions in force with respect to the sales force. So without question — and in no way trying to be defensive — the scripts took a hit. Last month, we averaged under 40% of that 2,500, which I'll quickly do the math on for everybody — that's fewer than 1,000 scripts per month. That comes as no surprise to us whatsoever. It's — when you launch products, you have to make an investment, and our investment and AMAG's investment was initially centered on education and awareness. As Carl mentioned, and I want to be very clear on this point, it's not — I mean, could we have turned on the faucet and started putting some marketing dollars in right away?
Steve Wills
executiveYes, in short. But we weren’t ready — not so much Palatin. With Vyleesi, though, we wanted the experience to be what we wanted it to be, whether for HCPs or consumers, and access wasn’t in place the way we believed it should have been, and that began with the pharmacies. So we’ve made some changes at the pharmacies that will actually improve and streamline patient access and the patient experience. And we also addressed distribution and coverage. Right now we’re at roughly 60% of how they calculate covered lives. We’ve brought in some excellent third parties to help us with this. We’re not territorial; we’ll get the best people we can to move forward and give us advice. Our goal is to reach 75%, if not 80%, of covered lives, which is a very good number to aim for. Whether we can accomplish that by the end of the year or the first quarter, we’re working on it. But we’re now — we’ve now taken the steps whereby we can now consider, if you will, a re-launch from a marketing standpoint. So that’s going to take place in the fourth quarter, could be within the next 30 days, no more than 60 days.
Steve Wills
executiveAt this point, let's just say the machine is in a far better spot — from a pharmacy perspective, from a coverage perspective, and from an access and distribution perspective. So when we put these marketing dollars to work in the fourth quarter, the odds of success are going to be much higher. Another thing I want to expand on: we aren't going to do what you'd call a — I mean, if this were one of the big companies, they'd be doing it, even with COVID-19 possibly having some impact, but they'd be pursuing a national launch from a marketing and promotion standpoint. That isn't what we'll be doing. We're going to do what we call — that's the term used for it — a geo-targeted, highly informed marketing approach. What that means is we'll be more snipers than a shotgun approach. We have lots of data. AMAG spent significant dollars on the launch. There's plenty of data, and some of it good, that came back in the first three or four months. We've engaged a third-party group that specializes in the digital marketing approach and social media, and we're very close to turning on that switch.
Steve Wills
executiveWe'll be aiming at several areas across the United States—quite a lot of regions. But for the regions where we've assembled metrics, and metrics, as always, we try to be data-driven: where the high prescribers are, where the consumers are who've already been engaged to some degree through the digital work AMAG has done and Palatin has continued? And the nice way—where do you want to fish? Carl, you want to fish where the fish are. So with that, we had the entire map of the United States showing where we believed the hotspots were. Carl, I then decided, let's overlay the insurance coverage on those hotspots, and that made some of the hotspots even more attractive. In certain areas we don't yet have as good coverage, and we're working on that. But those are the areas where, from the self-understanding standpoint, we're now prepared to move forward. So in summation, we believe we've made the modifications that needed to be made to the Vyleesi process and the program. And we're prepared, again within the next 30 days if not 60 days, to turn on that highly informed geo-targeted marketing approach. Now that was probably longer than you anticipated, Joe.
Steve Wills
executiveI might need to take a quick sip of water first. But let me stop here and check whether Carl and I answered that.
Joe Pantginis
analystThat was great. Thanks a lot for that, and I suppose this leads into another question. Well, first off, I don't want to put words in your mouth. But it really does look like you aren't simply sitting back and waiting to learn who will be the out-licensee for the drug or the partner. So this all sounds great. Thanks for that. So when it comes to out licensing or partnering, I guess what type of partner are you actually seeking? And I don't want to put you on the spot here, but is there any update on timing?
Carl Spana
executiveAlright, I'll accept that. Let me say a few words first, then hand things over to Steve. We want a partner that recognizes what Vyleesi is worth, believes it suits their women's health franchise and positioning, sees it as complementary to what they already have, and is ready to commit to genuinely pushing it forward in a manner that, in our view, delivers a return and, of course, investment as we proceed. One thing I'd like to highlight: there were certain complications in how AMAG approached trying to out-license, sell, or otherwise dispose of Vyleesi — whichever way you want to describe it. In that instance, it was bundled together with a different product. And they were also really seeking someone to simply step into the license agreement that was in place between AMAG and Palatin. So at this point — that created some difficulties with your partners; they weren't interested in both products. Some companies want something a bit different; it didn't fit — the licensing didn't fit how they were looking at it, so that's not too surprising to us. So since the acquisition, we've actually seen pretty solid interest. I'll now turn it over to Steve, and he can fill in some of the details on that and on the timing.
Steve Wills
executiveThanks, Carl. As ever, we'll let the data guide us. I mean, we do have some flexibility despite the cash sitting on our balance sheet as of June 30. We received $12 million from AMAG in connection with the transfer and the release. And another $4.3 million is due March 31. Showing the value is going to take some time. And I think that's the better path. We're making — we've made modifications, made corrections, whatever you'd like to call them, to put ourselves in a position to demonstrate Vyleesi's value in the marketplace. But even so, we've begun the process, and yes, I do have an outside banker that we work with. I wouldn't call it a process — it was similar to what AMAG did when they made their plans known, they wanted to divest the product. We're looking to see what kind of interest is out there. At this stage, maybe a few quarters down the line. And as Carl mentioned, we can be flexible — we have a lot of expertise across all the areas other than, if you will, the commercial side. So a traditional relicense, absolutely, we can consider that sort of a baton pass, if the Company can handle all the various functions.
Steve Wills
executiveHowever, there's also some flexibility for a company that might be more commercially focused and would like Palatin to take care of the CMC and perhaps certain aspects of the lifestyle — not the lifestyle, I mean the additional indications, clinical work, or that kind of effort. We could consider that too, given the flexibility and expertise we have. So, Nostradamus still hasn't gotten back to me, Joe. Therefore, I can't provide a date. That said, we feel quite confident that we've put the right pieces in place. So as things move forward, if something does begin to become more advanced, we would absolutely consider it. But the key point here is that we've already begun some discussions now, simply to see what might happen now or at some point down the road. I hope that's helpful to you.
Operator
operatorMichael Higgins from Ladenburg Thalmann has our final question.
Edward Marks
analystEdward here, filling in for Michael. Thanks, everyone, for taking their questions. We've just got a few more before we wrap up here. Regarding the Phase 3 trial in dry eye, I'm wondering how many sites you expect to enroll for that one.
Carl Spana
executivePhase 2 clearly involves far fewer sites, and we have strong sites in both the Northeast and the Southeast. For the Phase 3 pivotal study, the requirement is that it genuinely needs to reflect a more real-world situation. So you'd be looking at many clinical trial sites nationwide. These cases are very easy to find. An exact number — I don't have it off the top of my head. But generally, it would fall in the 50-plus range. You want enough so that you're spread out across the country and it truly represents how healthcare is practiced in the United States. So these generally tend to be between 50 to 100, depending on the size of the study, and these studies aren't particularly large — they're not multiple thousands of patients where you'd need quite a few sites. So you will be in that 50 to 100 throughout the country.
Edward Marks
analystMoving on to PL-9643, do you have any plans to bring in a partner for that asset? And taking a step back, I'd also like to know whether there are other pipeline assets you'd consider partnering, and what kind of timeframe you'd have in mind for such a partnership?
Carl Spana
executiveSure. So in the ocular space, we haven't been aggressive yet in thinking about or looking for or seeking a partnership. Partly that comes from the standpoint that we have potentially multiple opportunities there. And given the cash position we hold, we'd like to potentially consider holding some of these assets a bit longer, maybe even thinking about a possible commercial transition. There are plenty of smaller ocular companies with single products that may fit with certain types of opportunities we have. So, we haven't looked at it from that perspective yet. Obviously, we wouldn't do it, and obviously with certainly great strong positive data for PL-9643 and the interest coming in, we wouldn't partner. But right now, we haven't been aggressive, because we're looking more at a longer term strategy in the ocular space. Certainly, for ulcerative colitis, that's one where we actually do have earlier interest and have some ongoing discussions, particularly ex-U.S. And certainly, it's not one where you ask for proof-of-concept, we would — we really would have partnered or want to partner, not that it's a lack of belief in the product. I think it's just going to be a great mechanism for a variety of gastrointestinal diseases, but just because of the nature of that indication, demand for getting patients, the treatment options that are out there, it really makes sense we partnered with a company that has multiple assets in ulcerative colitis or another GI indications where they can position it appropriately and it really fits in their portfolio.
Carl Spana
executiveSo that isn't really something we'd take on by ourselves. And definitely, for anything in the heart failure space, while we wait for data to come out from that program, that would be a partnership — we wouldn't move ahead there alone, we'd partner. So I hope that helps?
Edward Marks
analystYes, certainly. I appreciate all of that detail. And just quickly, setting heart failure aside, I was wondering whether you could share any specifics on when that data might become available? Or is that not really something you guys control?
Carl Spana
executiveBasically, I'm certain we'll be watching it unfold live, so to speak. It's a Phase 2a trial. The patients are hospitalized, undergoing what's called a right heart workup, since they have preserved ejection fraction — often stemming from problems on the right side of the heart rather than the left. So the data will arrive in real time. My sense is you need a certain volume of patients, and I'd expect the middle of 2021 to be the earliest point when enough patients have come through for a solid read. The whole rationale behind this study rests on the fact that heart failure with preserved ejection fraction shows up predominantly, in many cases, among females and women. And no effective therapies exist as of yet. They account for 50%, nearly 50%, of heart failure cases involving ejection fraction. So, given the strong clinical need here, especially for women, and the American Heart Association Go Red program serves as a funding mechanism — or seeks to fund opportunities particularly suited to female patients. So this trial is really a proof-of-mechanism study, and there's a very — academic groups are extremely interested in this natriuretic peptide mechanism for this indication.
Carl Spana
executiveAnd it's really about figuring out whether this mechanism has a genuinely strong shot at working before you move into larger patient numbers. So it's an important study, and a positive outcome there would truly have the potential to transform treatment for patients with the ejection fraction — and certainly it's one where the critical need among these patients is very high. But I'd say the middle of next year is probably the earliest, and again, given the academic nature of it and the granting of it, that will have a relatively small impact on that.
Edward Marks
analystUnderstood, and thanks for all the specifics as well. Then just one last thing—in your prepared remarks, you said you'd submitted applications to a few different organizations for the COVID project they were working on. I'm curious, could you share which organizations those are that you're approaching?
Carl Spana
executiveYes, I mean, the other one — we’re going to focus on the one that interests us the most, which is called ACTIV, and that is a collaboration involving BARDA and, I believe, NIH plus a few other organizations, and the reason that one draws our interest most is that it functions more as a handoff. So under that process, if we are chosen to be part of the active program, they would truly take the compound over and actually run trials. And I think that would give the compound its best chance of success. There are a couple of out — there are a couple of other programs sponsored by NIH and FDA that we are examining and preparing applications for, but I think ACTIVE is the one where we already have the application in and are awaiting initial feedback, because that would be the one best suited to the compound. One of these we would prefer to avoid is that in the current situation we are beginning to receive advice that conducting studies in the U.S. would be difficult and that we might need to go to South America to have studies carried out. And so that is one reason why, when we think about how we proceed with the program, we really would like support in the U.S.
Carl Spana
executiveTaking ACTIV as an example would really help, since that lets you get into U.S. clinical trial sites far more easily and far more quickly.
Operator
operatorMuch appreciated. At this point, I'd like to hand the conference back to our speakers so they can offer any closing remarks.
Carl Spana
executiveCarl here once more. On my own behalf, along with Steve, the Board of Directors, and every Palatin employee, we truly want to express our appreciation to all of you for the time you've spent with us on today's call. As you know, since this was an annual call, it ran a bit longer than usual. We hope we've managed to get across how we assess and how enthusiastic we feel about the Vyleesi acquisition and about the ongoing work we're doing to build out an ocular franchise as well as other anti-inflammatory drugs based on the melanocortin system. Everyone here is pretty excited, and I mean the teams are putting in tremendous effort. We're genuinely anticipating 2021, with hopefully somewhat more normalization of operational activities and of life in general. And we're looking forward to the real success we'll achieve as we keep pushing our progress ahead. So I want to thank all of you once more, again, for joining the call. Please stay safe. Wear masks, social distance — like a broken record, but it works. And hopefully, we'll have some vaccines and newer treatments, maybe even PL-8177. So, thank you all, and have a great day.
Operator
operatorMuch appreciated. Everyone, that brings us to the end of today's call. You're welcome to hang up your phones now, and we hope the remainder of your week goes wonderfully. Thanks so much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.